
Azithromycin Does Not Improve Survival or Clinical Outcomes in Hospitalized Patients with COVID-19

Azithromycin Does Not Improve Survival or Clinical Outcomes in Hospitalized Patients with COVID-19
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Lancet. 2021 Feb 13;397(10274): 605-612.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Of the 9433 patients participating in the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial, 7763 were randomized to receive azithromycin plus standard care (n=2582), or standard care alone (n=5181; 837 eventually crossed over to receive azithromycin or tocilizumab but were still included in the analysis). The primary outcome of interest was all-cause mortality at 28 days. Secondary outco...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Join the Conversation
Please Login or Join to leave comments.